Product development

The drug AHRO-001 successfully completed a series of preclinical studies at UCLA Medical Center and Cedars-Sinai in Los Angeles, and Cleveland Clinic. The experiments confirmed the high efficiency of the designed product, and it was shown a significant decrease in the size of atherosclerotic plaques (95%). This therapeutic effect is not currently available for any of the classes of substances that are used for the treatment of dyslipidemia and prevention of atherosclerosis.
 
In June, 2013 the company has launched I/IIa clinical trial to assess safety, tolerability, pharmacokinetics and preliminary efficacy of a short-term reception of the lead compound AHRO-001 on patients with mild to moderate dyslipidemia. Preliminary results showed excellent compound tolerability as we as on the highest doses. 
 
In 2014 additional study initiated to evaluate preliminary efficacy of the drug in a long term treatment on patients with dyslipidemia.

In 2015 the company completed the phase IIa clinical trial.

CardioNova plans to develop several applications of AHRO-001:

  1. AHRO-001 in combination with a statin;
  2. AHRO-001 with the addition of dialysate;

And study AHRO-001 in other indications:

  • Treatment of obesity;
  • Transdermal lysis of localized fat deposits;
  • Lysis of lipomas.

Search form